Zhongjian Zhang

Zhongjian Zhang

Auto-generated profile, based on publicly available information

Zhongjian Zhang

Department of Cardiology, The General Hospital of Western Theater Command, 610083 Chengdu, Sichuan, China

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 July 2026 in Reviews in Cardiovascular Medicine
Verified
Journal Article
Open access
PDF file
ZZZhongjian Zhang
Zhongjian Zhang
TZTing Zeng
Ting Zeng
XLXiaoyu Li
Xiaoyu Li
ZHZhiling He
Zhiling He
SLShuang Li
Shuang Li
Heart failure (HF) is a significant cardiovascular syndrome with a high prevalence of morbidity and mortality across the globe. Meanwhile, lactate, a byproduct of glycolysis, has been implicated in myocardial hypoxia and disarranged energy metabolism and has drawn attention in the context of HF. In addition to serving as a highly sensitive biomarker, lactate might also contribute to myocardial remodeling and inflammation via multiple signaling pathways, thereby affecting disease course and prognosis; however, the mechanisms through which lactate impacts HF remain incompletely elucidated, and published results are contradictory. Therefore, this review encompassed lactate metabolism and the associated physiological and pathological functions in HF, underlining the clinical significance of lactate as a metabolic biomarker. Moreover, this review discussed recent progress targeting lactate metabolism or lactylation as potential treatments to promote a clearer understanding of the mechanistic aspects of metabolic regulation in HF and to guide clinical diagnosis and treatment.

18 May 2026 in Reviews in Cardiovascular Medicine
Verified
Journal Article
Open access
PDF file
XLXiaoyu Li
Xiaoyu Li
ZZZhongjian Zhang
Zhongjian Zhang
LTLuxun Tang
Luxun Tang
SLShuang Li
Shuang Li
Recent research has highlighted the pivotal role of RNA metabolism-related stress responses in the pathophysiology of cardiovascular diseases, particularly atherosclerosis, stroke, atrial fibrillation (AF), and heart failure (HF). Stress granules (SGs) are dynamic, membraneless organelles that arise during RNA metabolism via liquid-liquid phase separation (LLPS), in which mRNA associates with RNA-binding proteins (RBPs). SGs form following translation arrest in response to various external stimuli, resulting in cytoplasmic accumulation of mRNA and RBPs, which subsequently aggregate into membraneless messenger ribonucleoprotein (mRNP) granules, including Cajal bodies, SGs, P bodies, RNA transport granules, and germinal bodies. This review focuses specifically on SGs. SG formation is typically a transient and protective cellular response to stress; however, the dysregulation or persistence of SG formation has been implicated in a range of diseases, including cardiovascular conditions, neurodegenerative disorders, cancers, immune responses, and viral infections. Thus, this review examines the physiology and pathology of SGs, detailing the associated formation, composition, regulation, and function, with a particular focus on the involvement of SGs in cardiovascular diseases (CVDs) and potential therapeutic strategies targeting SGs. Moreover, this review outlines the complete life cycle of SGs and the associated implications in CVD. SGs originate near the endoplasmic reticulum (ER) and mitigate apoptosis by curbing mitochondrial production of reactive oxygen species. SGs can also disrupt the trafficking of specific cargo from the ER to the Golgi apparatus. Furthermore, SGs can repair damaged lysosomes and eventually undergo self-clearance via the autophagy-lysosome pathway. This model provides new perspectives for researchers in cardiovascular medicine, physicians, and translational medical researchers, and may advance our understanding of SG-related pathophysiology and facilitate the identification of novel therapeutic targets for CVDs.

18 May 2026
Verified
Open access
XLXiaoyu Li
Xiaoyu Li
ZZZhongjian Zhang
Zhongjian Zhang
LTLuxun Tang
Luxun Tang
SLShuang Li
Shuang Li
Recent research has highlighted the pivotal role of RNA metabolism-related stress responses in the pathophysiology of cardiovascular diseases, particularly atherosclerosis, stroke, atrial fibrillation (AF), and heart failure (HF). Stress granules (SGs) are dynamic, membraneless organelles that arise during RNA metabolism via liquid-liquid phase separation (LLPS), in which mRNA associates with RNA-binding proteins (RBPs). SGs form following translation arrest in response to various external stimuli, resulting in cytoplasmic accumulation of mRNA and RBPs, which subsequently aggregate into membraneless messenger ribonucleoprotein (mRNP) granules, including Cajal bodies, SGs, P bodies, RNA transport granules, and germinal bodies. This review focuses specifically on SGs. SG formation is typically a transient and protective cellular response to stress; however, the dysregulation or persistence of SG formation has been implicated in a range of diseases, including cardiovascular conditions, neurodegenerative disorders, cancers, immune responses, and viral infections. Thus, this review examines the physiology and pathology of SGs, detailing the associated formation, composition, regulation, and function, with a particular focus on the involvement of SGs in cardiovascular diseases (CVDs) and potential therapeutic strategies targeting SGs. Moreover, this review outlines the complete life cycle of SGs and the associated implications in CVD. SGs originate near the endoplasmic reticulum (ER) and mitigate apoptosis by curbing mitochondrial production of reactive oxygen species. SGs can also disrupt the trafficking of specific cargo from the ER to the Golgi apparatus. Furthermore, SGs can repair damaged lysosomes and eventually undergo self-clearance via the autophagy-lysosome pathway. This model provides new perspectives for researchers in cardiovascular medicine, physicians, and translational medical researchers, and may advance our understanding of SG-related pathophysiology and facilitate the identification of novel therapeutic targets for CVDs.